Capricor Therapeutics (CAPR) Non-Current Debt (2013 - 2024)
Capricor Therapeutics (CAPR) posted quarterly Non-Current Debt of $3.4 million for Q3 2024, little changed year-over-year from $3.4 million in Q4 2023, and little changed quarter-over-quarter from $3.4 million in Q2 2024.
Capricor Therapeutics (CAPR) Non-Current Debt (2013 - 2024) Analysis & Trends
Capricor Therapeutics' Non-Current Debt history runs 12 years deep, the most recent figure standing at $3.4 million for Q3 2024.
- In Q3 2024, Non-Current Debt changed 0.0% year-over-year to $3.4 million; the TTM figure through Sep 2024 stood at $3.4 million (changed 0.0% YoY), while the FY2023 annual figure was $3.4 million, changed 0.0% from the prior year.
- Non-Current Debt for Q3 2024 stood at $3.4 million, roughly flat from $3.4 million in the prior quarter.
- The five-year high for Non-Current Debt was $3.4 million in Q1 2020, with the low at $35469.0 in Q1 2021.
- The 5-year median for Non-Current Debt is $3.4 million (2020), against an average of $2.8 million.
- The sharpest annual moves came in 2021 and 2022: Non-Current Debt tumbled 98.95% in 2021, then jumped 9418.9% in 2022.
- Capricor Therapeutics' Non-Current Debt stood at $71471.0 in 2020, then soared by 4623.96% to $3.4 million in 2021, then changed by 0.0% to $3.4 million in 2022, then changed by 0.0% to $3.4 million in 2023, then changed by 0.0% to $3.4 million in 2024.
- Business Quant data shows CAPR's Non-Current Debt at $3.4 million in Q3 2024, $3.4 million in Q2 2024, and $3.4 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 3.38 Mn |
| Jun 30, 2024 | 3.38 Mn |
| Mar 31, 2024 | 3.38 Mn |
| Dec 31, 2023 | 3.38 Mn |
| Sep 30, 2023 | 3.38 Mn |
| Jun 30, 2023 | 3.38 Mn |
| Mar 31, 2023 | 3.38 Mn |
| Dec 31, 2022 | 3.38 Mn |
| Sep 30, 2022 | 3.38 Mn |
| Jun 30, 2022 | 3.38 Mn |
| Mar 31, 2022 | 3.38 Mn |
| Dec 31, 2021 | 3.38 Mn |
| Mar 31, 2021 | 35,469.00 |
| Dec 31, 2020 | 71,471.00 |
| Sep 30, 2020 | 3.38 Mn |
| Jun 30, 2020 | 178,233.00 |
| Mar 31, 2020 | 3.38 Mn |
| Dec 31, 2019 | 3.38 Mn |
| Sep 30, 2019 | 3.38 Mn |
| Jun 30, 2019 | 3.38 Mn |